Hinge Health, Inc. (HNGE) — SEC Filings
Hinge Health, Inc. (HNGE) — 15 SEC filings. Latest: DEFA14A (Apr 17, 2026). Includes 5 8-K, 4 S-1/A, 2 10-Q.
View Hinge Health, Inc. on SEC EDGAR
Overview
Hinge Health, Inc. (HNGE) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a DEFA14A filed on Apr 17, 2026: Hinge Health, Inc. filed a DEFA14A on April 17, 2026, which contains additional definitive proxy soliciting materials. The filing is related to the company's corporate actions and shareholder communications. The company is located at 455 Market Street, San Francisco, CA.
Sentiment Summary
Across 15 filings, the sentiment breakdown is: 3 bearish, 12 neutral. The dominant filing sentiment for Hinge Health, Inc. is neutral.
Filing Type Overview
Hinge Health, Inc. (HNGE) has filed 1 4, 1 144, 1 DEFA14A, 5 8-K, 2 10-Q, 4 S-1/A, 1 S-1 with the SEC between Mar 2025 to Apr 2026.
Filings by Year
Recent SEC Filings (15)
| Date | Form | Description | Risk |
|---|---|---|---|
| Apr 17, 2026 | DEFA14A | Hinge Health Files Definitive Proxy Materials | low |
| Mar 24, 2026 | 4 | Hinge Health Insider Budge James Files Form 4 on March 24, 2026 | |
| Mar 23, 2026 | 144 | Hinge Health Insider Budge James Files for Proposed Share Sale | |
| Nov 12, 2025 | 8-K | 8-K Filing | |
| Nov 7, 2025 | 10-Q | Hinge Health Revenue Soars 53% Amidst Exploding Operating Costs, Widening Losses | high |
| Nov 4, 2025 | 8-K | Hinge Health Files 8-K on Financials | low |
| Aug 13, 2025 | 8-K | Hinge Health Files 8-K for Other Events | low |
| Aug 11, 2025 | 10-Q | Hinge Health's Q2 Loss Widens to $55.2M Amid Revenue Growth | high |
| Aug 5, 2025 | 8-K | Hinge Health Files 8-K on Financials | low |
| May 23, 2025 | 8-K | Hinge Health Files 8-K with Corporate Updates | low |
| May 16, 2025 | S-1/A | Hinge Health Files S-1/A Amendment for IPO | medium |
| May 13, 2025 | S-1/A | S-1/A Filing | |
| May 5, 2025 | S-1/A | S-1/A Filing | |
| Apr 7, 2025 | S-1/A | Hinge Health Files S-1/A for IPO | medium |
| Mar 10, 2025 | S-1 | S-1 Filing |
Risk Profile
Risk Assessment: Of HNGE's 9 recent filings, 2 were flagged as high-risk, 2 as medium-risk, and 5 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $154.211M |
| Net Income | ($1.844M) |
| Cash Position | $261.342M |
| Total Assets | $769.802M |
Key Executives
- Daniel Perez
- Gabriel Mecklenburg
- James Pursley
Industry Context
Hinge Health operates in the rapidly growing digital health market, focusing on chronic condition management. The sector is characterized by increasing adoption of virtual care solutions, driven by technological advancements and a demand for more accessible and personalized healthcare. However, it faces intense competition from established healthcare providers and numerous innovative startups.
Top Tags
Digital Health (2) · Musculoskeletal Care (2) · Net Loss (2) · Revenue Growth (2) · Healthcare Technology (2) · ipo (2) · sec-filing (2) · proxy-filing (1) · shareholder-communication (1) · corporate-actions (1)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Q3 2025 Revenue | $154.211M | Increased 53.27% from $100.615M in Q3 2024 |
| Q3 2025 Net Loss | ($1.844M) | Compared to $0.341M net income in Q3 2024 |
| YTD 2025 Net Loss | ($560.356M) | Significantly widened from ($39.048M) in YTD 2024 |
| YTD 2025 R&D Expenses | $335.382M | Increased from $78.468M in YTD 2024, a 327% rise |
| YTD 2025 G&A Expenses | $304.976M | Increased from $46.559M in YTD 2024, a 555% rise |
| Deferred Revenue | $299.695M | Increased from $217.632M at Dec 31, 2024, indicating future revenue |
| Cash and Cash Equivalents | $261.342M | Decreased from $300.785M at Dec 31, 2024 |
| Class A Common Stock Shares Outstanding | 37,919,155 | As of October 30, 2025 |
| Class B Common Stock Shares Outstanding | 40,800,259 | As of October 30, 2025 |
| Revenue | $120.5M | for the three months ended June 30, 2025, up 35% year-over-year |
| Net Loss | $55.2M | for the three months ended June 30, 2025, widened from $40.1M in 2024 |
| Accumulated Deficit | $850.3M | as of June 30, 2025, increased from $795.1M at March 31, 2025 |
| Research and Development Expense | $30.1M | for the three months ended June 30, 2025, up from $25.5M in 2024 |
| General and Administrative Expense | $28.7M | for the three months ended June 30, 2025, up from $22.1M in 2024 |
| Revenue Growth | 35% | year-over-year for the three months ended June 30, 2025 |
Frequently Asked Questions
What are the latest SEC filings for Hinge Health, Inc. (HNGE)?
Hinge Health, Inc. has 15 recent SEC filings from Mar 2025 to Apr 2026, including 5 8-K, 4 S-1/A, 2 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of HNGE filings?
Across 15 filings, the sentiment breakdown is: 3 bearish, 12 neutral. The dominant sentiment is neutral.
Where can I find Hinge Health, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Hinge Health, Inc. (HNGE) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Hinge Health, Inc.?
Key financial highlights from Hinge Health, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for HNGE?
The investment thesis for HNGE includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Hinge Health, Inc.?
Key executives identified across Hinge Health, Inc.'s filings include Daniel Perez, Gabriel Mecklenburg, James Pursley.
What are the main risk factors for Hinge Health, Inc. stock?
Of HNGE's 9 assessed filings, 2 were flagged high-risk, 2 medium-risk, and 5 low-risk.
What are recent predictions and forward guidance from Hinge Health, Inc.?
Forward guidance and predictions for Hinge Health, Inc. are extracted from SEC filings as they are enriched.